---
title: "Sarkome: ASPSCR1-TFE3 Therapeutics"
description: "Sarkome is a single-asset entity (SAE) dedicated to identifying, validating, and licensing a selective protein degrader (SAR-001) for Alveolar Soft Part Sarcoma (ASPS)."
---

> Sarkome is a single-asset entity (SAE) dedicated to identifying, validating, and licensing a selective protein degrader (SAR-001) for Alveolar Soft Part Sarcoma (ASPS).

Welcome to the Sarkome documentation. Here you will find detailed information about our mission, the problem we are solving, our target, our platform, our roadmap, and our investment thesis.
